WARF bets big on new squad of drug hunters

Noted: WARF Therapeutics, unveiled last week at a meeting on campus, will help UW–Madison investigators deal with a difficult reality: Pharmaceutical companies are reluctant to license newly discovered biological entities (more commonly called “targets”), such …

Getting to know D2P

Bringing your dream to market is hard work. Navigating resources shouldn’t be. An interview with Discovery to Product (D2P) director Andrew Richards about leading the redesigned D2P program at UW–Madison, which is working to build …